Skip to main content
. 2014 Oct 3;4:54. doi: 10.1186/s13550-014-0054-2

Figure 3.

Figure 3

Therapeutic efficacy of anti-L1CAM RIT in combination with PTX. Tumour-bearing nude mice (n = 8) received 177Lu-DOTA-chCE7 (6 MBq, 50% MTA, i.v.) followed by PTX (600 μg, i.p.) 24 h later for combination therapies. Control mice received PBS, PTX or 6 MBq (25 μg) of 177Lu-labelled unspecific control IgG with or without PTX. (a) Mean relative tumour volume ± SD. Tumour growth curves were stopped when the first tumour in a treatment group reached 1,000 mm3. (b) Kaplan-Meier plots of the therapy experiment. (c) Development of body weight during therapy. Mean relative body weight ± SD.